ESMO event announcement.

By Saakshi Gupta
Senior Analyst, Oncology

In this overview, we look at the clinical trial landscape for trials that had data presented at ESMO 2023 to see which products are being developed, for which cancers, at what phase, in which geographies and what patient population are.

Immuno-oncology drugs are becoming an increasing presence in the anticancer pipelines. AstraZeneca dominated the space, followed by Roche, Merck & Co, and Bristol Myers Squib in terms of sponsoring trials.

Dashboard preview of the Primary Tested Drug.
Dashboard preview of the Sponsors.

Trial counts per cancer type. Non-small cell lung cancer is the most researched cancer type, followed by breast and colorectal cancers. Furthermore, most of the trials conducted are in phase II or III.

Dashboard preview of Disease. Dashboard preview of Trial Phase.

Looking at the patient population for these trials, we see the majority of the trials enroll patients based on genetic mutations or alterations.

Dashboard preview of the Trial Tag/Attribute.

With that being said, a good number of these trials are either first in human or are registrational i.e. pivotal clinical trials that are intended to be part of a regulatory submission to gain initial market approval.

Geographic Distribution - The United States holds the leading position in conducting maximum trials with non-small cell lung cancer being the focus of investigation followed by breast and colorectal cancers.

Dashboard preview of Countries.

Related resources

NOV 10, 2023

Cancer Vaccines: Active Companies and Competitor Landscape

We take a look at the global cancer vaccine development landscape, which companies are developing vaccines, for which cancers, and in which geographies.

FEB 01, 2022

Radiopharmaceuticals: A New Approach to Cancer Treatment

Radiopharmaceutical therapy is an emerging targeted approach to treat cancer, whose potential with specific tumor-associated targets is being recognized.

Liquid drop coming out of a pipette.
MAY 01, 2023
Conference Report

2023 Pre-ASCO Report

The Pharma R&D Annual Review 2023 Supplement looks at new active substances (NASs), drugs launched onto the market for the first time, during 2022